Could your weight loss medication before pregnancy impact your baby's health? New research is raising some intriguing, and potentially concerning, questions about the use of GLP-1 receptor agonists (like Ozempic, Wegovy, and Trulicity) before conception. While there's a potential upside – a reduced risk of gestational diabetes – there's also a signal suggesting a possible link to a higher risk of pre-eclampsia, a serious pregnancy complication. But here's where it gets controversial... is this a real effect of the drugs, or is something else at play?
A recent, albeit small, retrospective study presented at ObesityWeek 2025 sheds light on this complex issue. Researchers at the University of Florida (UF) investigated the connection between pre-pregnancy GLP-1 use and pregnancy outcomes. The study compared women who had taken GLP-1 medications in the year before becoming pregnant to those who hadn't. The results? Women who used GLP-1s had a significantly lower incidence of gestational diabetes (11% vs. 53%, P=0.005). That sounds amazing, right? But let's hold on a second...
Now, for the potential downside: the study also found a higher incidence of pre-eclampsia in the GLP-1 group (68% vs. 32%, P=0.023). Pre-eclampsia is a dangerous condition characterized by high blood pressure and organ damage, posing risks to both mother and baby. And this is the part most people miss... it may not be directly caused by the medication.
Dr. Dominick Lemas, the lead researcher from UF, emphasized that the medications studied were primarily liraglutide (Victoza, Saxenda), exenatide (Byetta), and dulaglutide (Trulicity). Only one participant had used semaglutide (Ozempic, Wegovy, Rybelsus). It's important to note that tirzepatide (Zepbound, Mounjaro) wasn't included, as it wasn't available during the study period.
It is also important to consider current FDA recommendations. The agency advises women to discontinue GLP-1 treatment at least two months before trying to conceive, due to potential risks observed in animal studies. However, Dr. Lemas rightly points out that this guidance isn't always followed in the real world, especially given that nearly half of all pregnancies in the U.S. are unplanned. This means many women may unknowingly be exposed to these medications during the early stages of pregnancy, or stop them shortly before conceiving. This poses the crucial question: how does discontinuing GLP-1s before pregnancy affect both the mother and the developing baby?
Dr. Lemas also highlighted the potential for "cardiometabolic rebound" after stopping GLP-1 therapy. This means that weight, blood pressure, and blood sugar levels can rapidly worsen after discontinuing the medication. This rebound effect, coinciding with the cardiovascular changes of early pregnancy, could potentially increase the risk of adverse outcomes for both mother and child. Think of it like a rubber band snapping back after being stretched – the body's systems can be thrown off balance.
The study itself involved a review of over 28,000 women who delivered singleton infants at the UF medical center between 2011 and 2021. The patient population was particularly noteworthy, as nearly one-third of the infants were born to mothers living in rural counties with significantly higher rates of maternal mortality, preterm birth, infant mortality, and maternal smoking compared to the rest of Florida. This highlights the importance of understanding the impact of these medications on vulnerable populations.
After matching 29 women who had used GLP-1s with similar women who hadn't (based on factors like diabetes diagnosis, obesity, hypertension, age, and race/ethnicity), researchers found that gestational diabetes was less common in the GLP-1 group (21% vs. 48%, P=0.027). However, pre-eclampsia was significantly more prevalent (69% vs. 38%, P=0.018). C-section rates were also higher in women who had used GLP-1s before pregnancy. Newborn birthweight, gestational age, fetal growth, and NICU admission rates were similar between the two groups.
The researchers theorize that the lower risk of gestational diabetes might be due to improved insulin sensitivity and sustained weight loss achieved before pregnancy. On the other hand, the potential cardiometabolic rebound after stopping the medication could contribute to increased blood pressure and gestational weight gain, potentially increasing the risk of pre-eclampsia. This is a hypothesis, and more research is needed to confirm it.
However, Dr. Sharon Herring of Temple University Lewis Katz School of Medicine raises a critical point: the study period included 2020-2021, a time when COVID-19 infections were rampant. COVID-19 has been linked to an increased risk of pre-eclampsia which introduces a confounding variable. The study did not account for COVID-19 infection status, making it difficult to determine whether the higher pre-eclampsia rates were truly related to GLP-1 use or were influenced by the pandemic. This is a HUGE consideration, and highlights the complexity of interpreting medical research.
Dr. Herring, who was not involved in the study, emphasized the need for caution in interpreting the pre-eclampsia findings. She suggested that researchers should delve deeper into the pre-eclampsia cases to better understand the potential contributing factors, especially given the already elevated risk of pre-eclampsia in women with high BMIs and the inflammatory effects of COVID-19 during pregnancy. Given the study's limitations, including its small size, specific patient demographics, and lack of data on factors like glycemic control, blood pressure patterns, lifestyle factors, and medication adherence, the findings should be interpreted with caution. The limited data on semaglutide and the absence of tirzepatide data also restrict the generalizability of the results, especially for women using GLP-1s for obesity management.
What do you think? Does this study change your perspective on GLP-1 use before pregnancy? Do you believe the potential benefits outweigh the possible risks? Could the higher pre-eclampsia rates be explained by other factors, like COVID-19? Share your thoughts and opinions in the comments below!
